THE MEDICAL NEWS |
Popis: from News-Medical.Net - Latest Medical News and Research from Around the World
|
||||||
Temporary heart pump before PCI shows no significant benefit18:43 The first randomized trial to test whether adding a small, temporary pump to allow the heart to rest and intentionally delaying percutaneous coronary intervention (PCI), also known as coronary angioplasty, for 30 minutes to reduce heart damage compared with standard immediate PCI in patients with heart attacks at risk for a large amount of heart damage found no significant difference between the two groups, the study's primary endpoint. The research was presented at the American College of Card… Left atrial appendage closure matches anticoagulants in AFib patients18:42 For patients with non-valvular atrial fibrillation (AFib) who had no contraindications to taking oral anticoagulants, the use of a device to close off the left atrial appendage in the heart—a small pouch where blood can pool and form dangerous clots—was comparable to standard medication therapy in reducing the combined rate of all-cause stroke, cardiovascular death and systemic embolism at three … Microaxial flow pump fails to reduce heart damage in STEMI trial18:09 Using a microaxial flow pump prior to and during cardiac stenting procedures for patients with severe heart attacks who don't have cardiogenic shock does not significantly reduce heart damage. Catheter-based approach improves prognosis in pulmonary embolism patients18:09 Patients who had low doses of clot-buster drugs delivered directly to the site of a pulmonary embolism (PE) via a catheter using ultrasound to enhance their effect had significantly better outcomes than those who received standard systemic anticoagulants, according to a study presented at the American College of Cardiology's Annual Scientific Session (ACC.26). Intensive cholesterol‑lowering therapy reduces first major cardiac event in high‑risk patients with diabetes16:29 Mass General Brigham researchers found that the intensive cholesterol‑lowering therapy evolocumab reduced the risk of a first major cardiovascular event in high‑risk patients who did not have known atherosclerosis (the build-up of plaque inside artery walls) but did have diabetes. Hypercortisolism found in many patients with resistant hypertension16:29 The MOMENTUM study found 27 percent of patients with resistant hypertension have hypercortisolism. This is a significant finding, demonstrating that hypercortisolism is more common in these patients than previously understood by researchers and clinicians. Evolocumab reduces cardiac events in high-risk diabetic patients15:56 The cholesterol-lowering therapy evolocumab reduced the risk of major adverse cardiac events by nearly one-third among patients who had no known significant atherosclerosis and had diabetes, according to a study presented at the American College of Cardiology's Annual Scientific Session. Home-delivered DASH diet improves blood pressure and cholesterol outcomes15:56 Black adults with high blood pressure who received dietitian counseling and home deliveries of groceries aligned with the DASH diet—meaning high in fruits, vegetables, whole grains, low-fat dairy, nuts, seeds, legumes and lean proteins—had an average overall reduction in systolic blood pressure of 7 mm Hg at three months overall and a 5 mm Hg reduction compared with participants who received only… Investigational drug lowers angiotensinogen but shows unclear blood pressure benefits15:56 The investigational drug tonlamarsen—which is designed to lower blood pressure by reducing the production of angiotensinogen, a protein that turns into the hormone that regulates blood pressure—caused a significant and sustained drop in angiotensinogen but its impact on blood pressure was less clear, according to a study presented at the American College of Cardiology's Annual Scientific Session. Intensive LDL cholesterol-lowering shows major benefits for heart disease patients15:22 Using cholesterol-lowering medications more intensively to achieve a more aggressive target for low-density lipoprotein cholesterol (LDL-C) reduced the rate of major cardiovascular events by one-third among patients with atherosclerotic cardiovascular disease (ASCVD), according to a study presented at the American College of Cardiology's Annual Scientific Session (ACC.26). |
Noviny
Sépie
Černé
Konzole
Modré
Přihlásit
Založit účet
Souhrn
Moje
Home
World
Sport
Economy
Technology
Culture
Life & Style
Other